To read the full story, subscribe or sign in.

Ono terminates development of Chordia’s cancer drug candidate

April 29, 2025

Ono Pharmaceutical Co. Ltd. terminated development of CTX-177 (ONO-7018), its ex-oncology candidate in-licensed from Chordia Therapeutics Inc. in December 2020 for up to ¥52.9 billion (US$370.37 million).

BioWorld BioWorld Asia Deals and M&A American Society of Hematology Cancer Small molecule Asia-Pacific Japan

Today's news in brief

BioWorld

BioWorld briefs for July 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 14, 2025.

Circode applies circRNA to heart disease drug R&D, in vivo CAR T

BioWorld

Shanghai Circode Biomed Co. Ltd. is set to begin clinical trials of HM-2002, a circular RNA (circRNA)-based drug for ischemic heart disease, having gained IND...

BD’s biosciences & diagnostics unit in $17.5B merger with Waters

BioWorld MedTech

Three months earlier than an expected update on a deal, Becton, Dickinson and Co. reported its biosciences and diagnostic solutions business will combine with...

Ultragenyx hit again, this time with a CRL in rare disease

BioWorld

Manufacturing issues are the latest problem for Ultragenyx Pharmaceutical Inc. to solve after last week’s disappointment in a phase III study to treat brittle...